Dr Michael Thurn has over two decades of experience in the life sciences and biotechnology industry, and has accumulated extensive knowledge in drug regulation, drug discovery, pre-clinical and clinical development across dermatology in Australia and the US. He has held various senior executive, managerial and board positions in listed and private companies. Dr Thurn has worked with the Therapeutic Goods Administration in Australia, led the clinical development of a topical acne treatment through to completion of Phase 2 clinical trial, and also led Spinifex Pharmaceuticals which was sold to Novartis in a $700m transaction.
Bio last updated 23 Feb 2019
BNiQ Network Graph
Displaying all related organisations and their related contacts. Hover over a node to display a link to the BNiQ page for that person or organisation.
Access to our data for Michael Thurn is only available to paid subscribers with BNiQ access.
The BNiQ search engine is Western Australia's most accurate and comprehensive business listings and searchable database.
Michael Thurn is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.
To see the data you will need to subscribe.
Total Shareholder Return as at 30/04/20
Chief Operating Officer, Head of Australian Operations, Executive Director since 2019
Year started and most recent title